Pan-European alternative asset manager Tikehau Capital and SPRIM Ventures, the venture capital arm of Singapore-based medical and scientific consultancy SPRIM Group, have reached a first close for their joint venture fund TKS1 with US$50 million in capital commitments. The fund will focus on early-stage opportunities in medical technology and life science companies in Singapore.